Latest Regulatory Approval News

MAC Copper Limited has entered a binding agreement for acquisition by Harmony Gold, offering shareholders a compelling 32% premium and signalling a major consolidation in the copper mining sector.

4DMedical has submitted its CT:VQ lung imaging technology for FDA clearance, aiming to disrupt the $1 billion US nuclear lung scan market with a non-nuclear, lower-cost alternative. Clinical studies show CT:VQ matches or exceeds existing nuclear imaging in accuracy and patient experience.

Beacon Minerals has secured an option agreement to acquire the Wealth of Nations gold tenements near its Jaurdi processing plant, setting the stage for renewed exploration and potential resource growth.

M3 Mining Limited has abandoned its energy sector acquisition plans, selling its M3 Energy subsidiary to Jerboa Energy Ltd and recommitting to its core mineral exploration projects.

PainChek Limited has secured a pivotal reseller and integration deal with Eldermark Software, positioning its AI-driven pain assessment app for a major US market rollout pending FDA approval.

Optiscan Imaging Ltd has reached a pivotal milestone with the completion of its cloud-based telepathology software MVP, enabling secure, real-time remote collaboration for digital pathology.

Sunshine Metals has secured a binding agreement to acquire the high-grade Sybil Epithermal Gold Project near Charters Towers, Queensland, aiming to fast-track near-surface gold production. The acquisition, valued at A$1.225 million, aligns with Sunshine’s strategy to expand its district presence and leverage underexplored epithermal systems.

Vulcan Energy has begun drilling the first new well for its Phase One Lionheart Project in Germany, marking a critical step toward expanding its renewable geothermal energy and lithium production capacity.

Cauldron Energy Limited has announced a fully underwritten entitlement offer to raise nearly $2 million, aimed at advancing its Yanrey Uranium Project and shoring up working capital. The offer, priced at $0.006 per share, could reshape shareholder control dynamics depending on participation.

Recce Pharmaceuticals has secured a significant patent acceptance in China for its RECCE® anti-infectives, broadening its intellectual property footprint in the world’s second-largest pharmaceutical market.

OncoSil Medical has launched a $8.7 million capital raising via a Share Purchase Plan and Placement, seeking shareholder approval for options issuance and a 400:1 share consolidation.

OncoSil Medical has secured $8.7 million through a placement and share purchase plan to fund commercialization of its pancreatic cancer treatment device, aiming for positive cash flow by mid-2026. Near-completion clinical trials could soon unlock broader market access.